Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

Pfizer and Valneva reported their experimental Lyme disease vaccine achieved greater than 70% efficacy in a late-stage trial. The result materially de-risks the program and could support future regulatory filings and a commercial launch if safety and durability are confirmed. Expect a modest positive re-rating of both companies' shares and increased investor focus on the Lyme vaccine opportunity.

Analysis

Pfizer and Valneva reported their experimental Lyme disease vaccine achieved greater than 70% efficacy in a late-stage trial. The result materially de-risks the program and could support future regulatory filings and a commercial launch if safety and durability are confirmed. Expect a modest positive re-rating of both companies' shares and increased investor focus on the Lyme vaccine opportunity.